Unleashing the power of next generation cancer treatments
View Pipeline
Pipeline
AmMax has built a robust oncology pipeline by leveraging its translational expertise with its lead program, AMB-066, supported by compelling preclinical data and a well-established safety profile across 6 completed clinical trials.
Dr. Van Morris, Principal Investigator, MD Anderson Cancer Center, discusses NCT06617858:
a Phase 2 proof of concept study to test AMB-066 for treating CRC MRD. This trial is currently recruiting.
Latest News
All News
Mar 11, 2024